One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's result is not the same thing as a finished cure.
More Than a Familiar Fundraising Night
The organization, formerly known as JDRF, says its New York Promise Gala has raised more than $85 million over five decades. That is serious philanthropic muscle, not loose change shaken out of tuxedo pockets. The money supports grants intended to move potential type 1 diabetes cures into clinical trials and, ultimately, toward treatments people can actually use. For anyone watching the health-care innovation pipeline, that middle stretch between promising science and human evidence is where the hard work lives.
Este Haim, the GRAMMY-nominated musician who has lived with type 1 diabetes since her diagnosis at 14, is emceeing. Her involvement makes sense beyond the celebrity gloss. Type 1 diabetes does not take nights off for touring, work, parenting, or gala speeches. It is a daily management burden, and voices with firsthand experience can keep an event like this grounded in the people research is supposed to serve.
Katie Beth Hand's Result Deserves Both Hope and Restraint
Katie Beth Hand, a mother of four, participated in a Breakthrough T1D-funded cell therapy clinical trial and no longer requires insulin, according to the organization. That is a remarkable outcome by any reasonable measure. Hand describes the freedom from years of insulin doses and constant health decisions in terms that ought to stop anybody in their tracks.
Still, this is medicine, not a ticker tape parade. Clinical trial results require careful evaluation: durability, safety, the number and type of participants, and whether an approach can be delivered broadly all matter. The notes do not provide those details, so nobody should invent them or treat Hand's experience as a universal answer for the nearly 9 million people globally living with type 1 diabetes. The right takeaway is encouraging, not breathless. Philanthropic funding helped push work into a clinical setting where a life-changing result became possible. That is precisely why sustained research support matters.
The Disease Does Not Leave Much Room for Complacency
Type 1 diabetes is an autoimmune condition in which the pancreas makes very little or no insulin. Its onset is unrelated to diet or lifestyle, and it can arrive at any age. People with T1D depend on insulin therapy and must manage the threat of high and low blood sugar as well as potential long-term damage involving the kidneys, eyes, nerves, and heart. There is currently no cure.
Those facts are the unglamorous backbone beneath the evening's auctions and speeches. They also explain why “advancing toward cures” is not empty gala language when it is paired with real research grants and clinical trials. Progress in this field has to be measured in practical terms: fewer burdens, safer days, better treatment choices, and eventually interventions that can change the underlying disease. Big promises are cheap in health care. Credible steps are not.
A Personal Commitment With Real Fundraising Weight
This year's Humanitarian of the Year, Peter Hill, brings the personal and financial sides together without much pretense. Hill is a senior managing director at Ramirez & Co. and a past president of the Breakthrough T1D New York City Chapter Board. He has helped raise more than $2 million for the organization, including over $500,000 through its Run program. His daughter Sheila was diagnosed in 2019, and several family members live with T1D.
That kind of connection tends to outlast the photo-op circuit. Hill's recognition is a reminder that advocacy funding often gets built one committed family, employer, donor, and volunteer at a time. His daughter and her husband, San Diego Padres pitcher and former New York Yankee Michael King, are expected to attend, adding a public face to a cause that is painfully private for many families.
Where the Money Goes Is the Point
The program begins at 6:00 p.m. with a cocktail reception and silent auction, then moves into dinner, a live auction, and Fund A Cure. Breakthrough T1D says 100% of Fund A Cure contributions go directly to its mission. Donors should always care about that distinction. A clean claim about mission-directed giving is more meaningful than vague talk about “supporting a cause.”
Tonight is not proof that type 1 diabetes has been solved. It is evidence that the community has kept showing up for 53 years, and that research funding can move from a hopeful concept to a clinical trial with tangible human stakes. In a world awash in grand medical claims, that is a sturdy, sober reason to pay attention.